ADR3, a next generation i-body to human RANKL, inhibits osteoclast formation and bone resorption

Osteoporosis is a chronic skeletal condition characterized by low bone mass and deteriorated microarchitecture of bone tissue and puts tens of millions of people at high risk of fractures. New therapeutic agents like i-bodies, a class of next-generation single-domain antibodies, are needed to overcome some limitations of conventional treatments.

Citation:
Qiu H, Hosking C, Rothzerg E, …… Kuek V, Jin H, et al. ADR3, a next generation i-body to human RANKL, inhibits osteoclast formation and bone resorption. J Biol Chem. 2023;299(2)

Keywords:
RANKL; bone resorption; i-body; osteoclast; osteoporosis

Abstract:
Osteoporosis is a chronic skeletal condition characterized by low bone mass and deteriorated microarchitecture of bone tissue and puts tens of millions of people at high risk of fractures. New therapeutic agents like i-bodies, a class of next-generation single-domain antibodies, are needed to overcome some limitations of conventional treatments.